Pipeltro (Doravirine) and Delstrigo (Doravirine, Lamivudine, Tenofovir), the HIV treatment by MSD, are the two major human immunodeficiency virus. And, were declared "Conditional Coverage" at the first step of the reimbursement if it was accepted below the appraised amount.

On the 3rd, the HIRA held the 5th Pharmaceutical Benefits Advisory Committee in 2021, and conducted a review of benefit adequacy for new drugs related to HIV and asthma. Pipeltro, a combination of other anti-retroviral drugs for HIV-1 treatment, and Delstrigo for adult patients were proposed, but MSD's submission to the HIRA was higher than that of the Pharmaceutical Benefits Advisory Committee.

Both Pipeltro and Delstrig